AbbVie joins US government pilot to test drug discount rebates

AbbVie

02/10/2026 21:51

Oct 2 (Reuters) - US drugmaker AbbVie ABBV.N said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
Here are some details:
The pilot will begin on January 1, 2027, under the government's 340B program, which helps hospitals and clinics serving low-income patients buy medicines at a discount.
Under the new model, eligible healthcare providers will submit claims through a platform called Beacon to obtain 340B pricing on AbbVie's cancer drug Imbruvica, irritable bowel syndrome treatment Linzess and antipsychotic drug Vraylar.
AbbVie said it would provide healthcare groups with free access to the system, as well as customer service and special assistance for providers facing operational difficulties.
The rebate test will help improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect, the company said.
AbbVie said it plans to work closely with federal health regulators and healthcare providers throughout the rollout.
Besides AbbVie, Amgen AMGN.O, AstraZeneca AZN.L, Pfizer PFE.N and Bristol Myers Squibb BMY.N are among the companies approved for the federal pilot.

 (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
 ((Kamal.Choudhury@thomsonreuters.com;))